Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    ACC CardiaCast: Emerging Data in SGLT2 Inhibitors

    ACC CardiaCast: Emerging Data in SGLT2 Inhibitors

    FromACC CardiaCast

    Start listeningView podcast show

    ACC CardiaCast: Emerging Data in SGLT2 Inhibitors

    FromACC CardiaCast

    ratings:
    Length:
    12 minutes
    Released:
    Jun 29, 2018
    Format:
    Podcast episode

    Description

    This podcast discusses new data pertaining to the class of SGLT2 inhibitors in the treatment of diabetes and its cardioprotective properties. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the results of the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial will help prepare you to better treat your patients.
    Released:
    Jun 29, 2018
    Format:
    Podcast episode

    Titles in the series (96)

    This occasional series from the American College of Cardiology offers the latest in clinical education and features an exploration of current research and interviews with cardiovascular experts.